Filtered By:
Education: Learning
Nutrition: Organic
This page shows you your search results in order of date.
Order by Relevance | Date
Total 20 results found since Jan 2013.
How John Fetterman Came Out of the Darkness
When he looks back on the past year—a year in which he nearly died, became a U.S. Senator, and nearly died again—it is the debate that John Fetterman identifies as the breaking point.
“The debate lit the mitch,” he says, then shakes his head in frustration and tries again. The right word is there in his brain, but he struggles to get it out. “Excuse me, that should be lit the mitch—” He stops and tries again. “Lit the match,” he says finally.
Oct. 25, 2022: the date is lodged in his mind. “I knew I had to do it,” he tells me. “I knew that the vote...
Source: TIME: Health - July 20, 2023 Category: Consumer Health News Authors: Molly Ball Tags: Uncategorized Congress Cover Story Exclusive feature uspoliticspolicy Source Type: news
Billions With Nutrition Deficiency!?
Almost no one gets enough selenium. Officially, at least a billion — with a B — people have a selenium deficiency.1
But I suspect the numbers are much higher than that.
You can’t get enough selenium from food alone anymore. That’s true even if you eat a healthy, varied diet. And you can thank Big Agra for that.
With their harsh pesticides, synthetic fertilizers, and single-crop strategy, these massive farms have stripped the nutrients out of the soil. No nutrients in the soil mean no nutrients in the food.
All of this makes it difficult — if not impossible — to get even some of the daily selenium you need to ...
Source: Al Sears, MD Natural Remedies - May 15, 2023 Category: Complementary Medicine Authors: Jacob Tags: Anti-Aging Nutrition Source Type: news
ERLEADA ® (apalutamide), First-and-Only Next-Generation Androgen Receptor Inhibitor with Once-Daily, Single-Tablet Option, Now Available in the U.S.
HORSHAM, Pa., April 3, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the availability of an additional tablet strength of ERLEADA® (apalutamide) in the United States. The introduction of the 240mg tablet provides the first-and-only option for a once-daily, single-tablet Androgen Receptor Inhibitor (ARI) approved for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC) and for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).With two strengths available, healthcare professionals will have the flexibility to...
Source: Johnson and Johnson - April 3, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Acori Tatarinowii Rhizoma: A comprehensive review of its chemical composition, pharmacology, pharmacokinetics and toxicity
Acori Tatarinowii Rhizoma (ATR, Shi Chang Pu in Chinese), a natural product with multiple targets in various diseases. This review provides the comprehensive summary of the chemical composition, pharmacological effects, pharmacokinetics parameters and toxicity of ATR. The results indicated that ATR possesses a wide spectrum of chemical composition, including volatile oil, terpenoids, organic acids, flavonoids, amino acids, lignin, carbohydrates and so on. Accumulating evidence from various studies has shown that ATR exerts a wide range of pharmacological properties, including protecting nerve cells, alleviating learning an...
Source: Frontiers in Pharmacology - March 16, 2023 Category: Drugs & Pharmacology Source Type: research
Janssen Data at ASCO GU Support Ambition to Transform Treatment of Prostate and Bladder Cancer Through Precision Medicine and Early Intervention
RARITAN, N.J., February 13, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced plans to present more than 20 abstracts featuring seven oncology therapies from its robust portfolio and pipeline at the annual American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium, taking place in San Francisco on February 16-18. Building on more than a decade of leadership in the development of medicines for people diagnosed with GU cancers, Janssen will present data demonstrating its ambition to advance patient-centered treatment through precision medicine, real-world evidence a...
Source: Johnson and Johnson - February 13, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
New ERLEADA ® (apalutamide) Analysis Demonstrates Rapid, Deep Prostate-Specific Antigen (PSA) Response in Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
SAN FRANCISCO, Feb. 14, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new real-world evidence data showing the initiation of ERLEADA® (apalutamide) results in high rates of rapid and deep prostate-specific antigen (PSA) response among patients with metastatic castration-sensitive prostate cancer (mCSPC). In a separate post-hoc analysis of the registrational Phase 3 SPARTAN and TITAN studies, rapid and deep PSA responses with ERLEADA® were associated with improvement in patient-reported outcomes (PROs) related to quality of life, physical wellbeing, pain, and fatigue intensity. The...
Source: Johnson and Johnson - February 14, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen Data at ASCO GU Demonstrate Longstanding Leadership in Prostate Cancer and Commitment to Advancing Potential New Therapeutic Options for Genitourinary Cancers
Raritan, NJ, Feb. 1, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that 17 presentations will be featured at the 2022 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, taking place in San Francisco and virtually from February 17-19. Building on its long-term leadership in prostate cancer, Janssen is committed to advancing innovative treatments and transforming patient experiences, while focusing on research that may drive better outcomes for people across the genitourinary cancer spectrum. Data to be presented include Phase 3 results for the selective ...
Source: Johnson and Johnson - February 1, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Based on voxel-based morphological analysis to investigate the effect of acupuncture-rehabilitation therapy on hippocampal volume and its neuroprotective mechanism in patients with vascular cognitive impairment with type 2 diabetes mellitus: A study protocol
Discussion:
This trial can clarify the effect of acupuncture-rehabilitation therapy on hippocampal volume and its intervention mechanism on oxidative stress injury in VCI patients with T2DM, and clarify the scientific connotation of its neuroprotective mechanism in the VCI patients with T2DM, in order to provide a theoretical basis for the clinical application of acupuncture-rehabilitation therapy in the treatment of VCI.
Trial registration:
Chinese Clinical Trial Registry (ChiCTR), ChiCTR2100047803. Registered 26 June, https://www.chictr.org.cn/showproj.aspx?proj=128707
Source: Medicine - December 23, 2021 Category: Internal Medicine Tags: Research Article: Study Protocol Clinical Trial Source Type: research
ERLEADA ® (apalutamide) Oral Presentations Demonstrate Importance of Prostate Specific Antigen (PSA) as Key Efficacy Indicator and Show Strong Patient Adherence Rates
September 11, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data demonstrating robust prostate-specific antigen (PSA) response and strong adherence rates in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) treated with ERLEADA® (apalutamide) in the real-world clinical setting. The strong PSA response was also seen in a separate post-hoc analysis that showed a correlation between rapid and deep PSA response and prolonged survival in both metastatic castration-sensitive prostate cancer (mCSPC) and nmCRPC. The post-hoc analysis also suppor...
Source: Johnson and Johnson - September 12, 2021 Category: Pharmaceuticals Source Type: news
Janssen Demonstrates Commitment to Advancing Science and Innovation in the Treatment of Solid Tumors at ESMO Annual Congress
September 8, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than ten data presentations from its lung cancer, bladder cancer and prostate cancer portfolio and pipeline will be featured during the European Society for Medical Oncology (ESMO) Annual Congress 2021 virtual meeting, September 16–21. Further details about these data and the science Janssen is advancing will be made available throughout ESMO via the Janssen Oncology Virtual Newsroom.“With a diverse oncology portfolio and pipeline spanning bladder cancer, lung cancer and prostate cancer, Janssen...
Source: Johnson and Johnson - September 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Striving to Deliver Better Outcomes: Janssen to Showcase Commitment to Advancing Science for Genitourinary Cancers at AUA 2021
August 31, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today multiple company-sponsored presentations in prostate and bladder cancers will be highlighted at the virtual 2021 American Urological Association Annual Meeting (AUA 2021), September 10-13. “Janssen maintains a strong commitment to advancing innovation and new therapeutic options for patients with genitourinary malignancies. As the treatment of genitourinary cancers becomes more complex, we continue to work with urologists and their teams to improve outcomes for patients across the continuum of disease,” sai...
Source: Johnson and Johnson - August 31, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
Neuroimaging and Neurolaw: Drawing the Future of Aging
Vincenzo Tigano1, Giuseppe Lucio Cascini2, Cristina Sanchez-Castañeda3, Patrice Péran4 and Umberto Sabatini5*
1Department of Juridical, Historical, Economic and Social Sciences, University of Magna Graecia, Catanzaro, Italy
2Department of Experimental and Clinical Medicine, University of Magna Graecia, Catanzaro, Italy
3Department of Clinical Psychology and Psychobiology, University of Barcelona, Barcelona, Spain
4ToNIC, Toulouse NeuroImaging Center, Université de Toulouse, Inserm, UPS, Toulouse, France
5Department of Medical and Surgical Sciences, University of Magna Graecia, Catanzaro, ...
Source: Frontiers in Endocrinology - April 7, 2019 Category: Endocrinology Source Type: research
Are Eggs Healthy? Here ’s What the Experts Say
Eggs dominate the menus of all sorts of breakfast spots, from fast-food chains to organic cafes. But the humble egg comes with a lot of questions: Will eggs raise your cholesterol? Should you order an egg-white omelet or embrace the yolks? And what about organic eggs — are they really more nutritious?
Whether you eat them every day or just occasionally, there’s plenty to learn about how to incorporate eggs into a healthy diet. Here, dietitians weigh in on what you need to know about nutrition in eggs.
Are eggs healthy?
Nutrition experts agree that the protein and vitamins in eggs make them a healthy option. &ld...
Source: TIME: Health - December 5, 2018 Category: Consumer Health News Authors: Cassie Shortsleeve Tags: Uncategorized Diet/Nutrition Source Type: news
Are Eggs Healthy? Here ’s What Experts Say
Eggs dominate the menus of all sorts of breakfast spots, from fast-food chains to organic cafes. But the humble egg comes with a lot of questions: Will eggs raise your cholesterol? Should you order an egg-white omelet or embrace the yolks? And what about organic eggs — are they really more nutritious?
Whether you eat them every day or just occasionally, there’s plenty to learn about how to incorporate eggs into a healthy diet. Here, dietitians weigh in on what you need to know about nutrition in eggs.
Are eggs healthy?
Nutrition experts agree that the protein and vitamins in eggs make them a healthy option. &ld...
Source: TIME: Health - December 5, 2018 Category: Consumer Health News Authors: Cassie Shortsleeve Tags: Uncategorized Diet/Nutrition Source Type: news
10 Ways to Keep Your Heart Healthy
No one ever had fun visiting the cardiologist. Regardless of how good the doc might be, it’s always a little scary thinking about the health of something as fundamental as the heart. But there are ways to take greater control—to ensure that your own heart health is the best it can be—even if you have a family history of cardiovascular disease.
Although 50% of cardiovascular-disease risk is genetic, the other 50% can be modified by how you live your life, according to Dr. Eugenia Gianos, director of Women’s Heart Health at Lenox Hill Hospital in New York City. “This means you can greatly ...
Source: TIME: Health - October 17, 2018 Category: Consumer Health News Authors: Lisa Lombardi and Jamie Ducharme Tags: Uncategorized Baby Boomer Health heart health Source Type: news
